BIONDVAX PHARMACEUTICALS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on

BIONDVAX PHARMACEUTICALS LTD.

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

To Be Held on March 24, 2020

The Annual General Meeting

of Shareholders of BiondVax Pharmaceuticals Ltd. (the "Company") will be held at the offices of Gross, Kleinhendler,

Hodak, Halevy, Greenberg, Shenhav & Co., One Azrieli Center, Tel Aviv 6701101, Israel on March 24, 2020 at 4:00 p.m. Israel

time, or at any adjournments thereof (the "General Meeting") for the following purposes:

In addition, shareholders

at the General Meeting will have an opportunity to review and ask questions regarding the financial statements of the Company for

the fiscal years ended December 31, 2018.

The Company is currently

unaware of any other matters that may be raised at the General Meeting. Should any other matters be properly raised at the General

Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.

Only holders of record

of ordinary shares, no par value (the "Ordinary Shares"), and holders of record of ADSs, evidenced by American Depositary

Receipts issued by The Bank of New York Mellon at the close of business on February 18, 2020 shall be entitled to receive notice

of and to vote at the General Meeting (the "Record Date").

The Board of Directors

recommends that you vote FOR each of the proposals.

plan to attend the General Meeting, it is important that your Ordinary Shares be represented. Accordingly, you are kindly requested

to complete, date, sign and mail the proxy to be provided separately at your earliest convenience. Execution of a proxy will not

in any way affect a shareholder's right to attend the General Meeting and vote in person, and any person giving a proxy has

the right to revoke it at any time before it is exercised.

holders should return their proxies by the date set forth on their form of proxy.

either registered in the Company's shareholders' register in Israel or who hold Ordinary Shares through members

of the Tel Aviv Stock Exchange, and who intend to vote their Ordinary Shares either in person or by proxy, must deliver to the

Company's offices, c/o Mr. Uri Ben Or, Chief Financial Officer, at BiondVax Pharmaceuticals Ltd., Jerusalem BioPark, 2nd

Floor, Hadassah Ein Kerem Campus, Jerusalem 9112001, Israel, no later than March 24, 2020, at 10:00 a.m. Israel time, an ownership

certificate confirming their ownership of the Company's Ordinary Shares on the Record Date, which certificate must be issued

or approved by a recognized financial institution, as required by the Israeli Companies Regulations (Proof of Ownership of Shares

for Voting at General Meeting) of 2000, as amended. Shareholders either registered in the

Company's shareholders' register in Israel or who hold Ordinary Shares through members of the Tel Aviv Stock

Exchange may vote through the attached proxy by completing, dating, signing and mailing the proxy to the Company's offices,

c/o Mr. Uri Ben Or at BiondVax Pharmaceuticals Ltd., Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem 9112001,

Israel, so that it is received by the Company no later than March 22, 2020, at 4:00 p.m. Israel time.

wishing to express their position on an agenda item for this General Meeting may do so by submitting a written statement ("Position

Statement") to the Company's offices, c/o Mr. Uri Ben Or at at BiondVax Pharmaceuticals Ltd., Jerusalem BioPark, 2nd

Floor, Hadassah Ein Kerem Campus, Jerusalem 9112001, Israel, by no later than March 15, 2020. Any Position Statement received that

is in accordance with the guidelines set by the Companies Law will be furnished to the U.S. Securities and Exchange Commission

(the "Commission") on Form 6-K, and will be made available to the public on the Commission's website at http://www.sec.gov.

Should no legal quorum

be present one-half hour after the scheduled time, the General Meeting will be adjourned to one week from that day, at the same

time and place, i.e. on March 31, 2020, at 4:00 p.m. (Israel Time) at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg,

Shenhav & Co., One Azrieli Center, Tel Aviv 6701101, Israel. Should such legal quorum not be present half an hour after the

time set for the adjourned meeting, any number of shareholders present, in person or by proxy, will constitute a legal quorum.

This Notice and the documents

mentioned therein, as well as the proposed resolutions on the agenda, will be made available at the Company's registered

office on Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, Tel: +972-(8)-930-2529, Sunday

through Thursday between 10:00-15:00, and also will be made available to the public on the Company's website http://www.biondvax.com,

the Commission's website at http://www.sec.gov.